60
Participants
Start Date
April 9, 2020
Primary Completion Date
May 31, 2023
Study Completion Date
December 1, 2023
ATG-010 60 mg, orally, twice weekly, each 4 week (28-day) a cycle
Enrolled patients will be treated with a fixed dose, 60 mg of ATG-010, orally, twice weekly, each 4 week (28-day) a cycle.
Beijing Cancer Hospital, Beijing
Peking University Third Hospital, Beijing
The Second Hospital of Dalian Medical University, Dalian
The First Bethune Hospital of Jilin University, Changchun
Harbin Medical University Cancer Hospital, Harbin
Fudan University Shanghai Cancer Center, Shanghai
The First Affilate Hospital with Nanjing Medical University, Nanjing
Anhui Province Cancer Hospital, Hefei
Tianjin blood research institute, Tianjin
Tianjin Medical University Cancer Institute & Hospital, Tianjin
Cancer Hospital of the University of the Chinese Academy of Sciences, Hangzhou
Chongqing Universtity Cancer Hospital, Chongqing
Hunan Cancer Hospital, Changsha
Hubei Cancer Hospital, Wuhan
Wuhan Union Hospital, Wuhan
Henan Cancer Hospital, Zhengzhou
Sun Yat-Sen University Cancer Center, Guangzhou
West China Hospital of Sichuan University, Chengdu
Antengene Corporation
INDUSTRY